These compounds remain without approved clinical trial evidence of safety and effectiveness
BPC-157 remains investigational by comparison, with animal data suggesting potential but no controlled human trials confirming cardiovascular benefits
Food and Drug Administration (FDA), and are not intended to diagnose, treat, cure, or prevent any disease or medical condition
Injection route: Subcutaneous, near the injury site or abdominal fat pad depending on indication Dose and frequency: Set at your APRN intake based on indication, body weight, and injury severity Cycle length: 4 to 8 weeks, with a rest period between cycles All Perfect B protocols start with a full medical intake, not a vial and a pamphlet BPC-157 Injection Dosage: Subcutaneous Protocol Step by Step Subcutaneous injection delivers BPC-157 directly into the fat tissue just below the skin, where it is absorbed into the bloodstream and distributed systemically
Summary: AOD 9604 and retatrutide are both unlicensed investigational compounds in the UK, and there is no clinical evidence or regulatory guidance supporting their combined use
